Gyre Therapeutics, Inc. Common Stock (GYRE) — Analysis Summary
Gyre Therapeutics, Inc. Common Stock (GYRE) has a market cap of $573.44M with year-over-year revenue growth of +10.2%. Net margin stands at 8.5%. The stock trades at a P/E ratio of -154.5.
Key Takeaways
- Revenue changed +10.2% year-over-year
- Net margin of 8.5%
- P/E ratio of -154.5
Compared to other companies in the PHARMACEUTICAL PREPARATIONS sector, GYRE posted revenue growth of +10.2% and trades at a P/E of -154.5.
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.